Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Hb95 Fertility Preservation topic
No spam. Unsubscribe anytime.
Committee approves substitute for fertility‑preservation coverage bill after expert testimony
Summary
The committee adopted a committee substitute and recommended a due pass on the Health Care Purchasing / Insurance Code substitute for HB 95 to require fertility‑preservation services when medically indicated; the original bill received a do‑not‑pass recommendation and the substitute passed by recorded committee action.
The House Health & Human Services Committee considered a committee substitute for HB 95 and recommended its passage after hearing testimony from oncologists, nonprofit patient advocates and fertility‑preservation experts. The substitute would amend the Health Care Purchasing Act and the New Mexico Insurance Code to require coverage for fertility‑preservation services for enrollees whose disease or medically necessary disease treatment may lead to infertility; the new sections were slated to take effect Jan. 1, 2026 in the substitute language presented to the committee.
Expert and advocacy testimony: Dr. Sandra Pien (oncologist) told the committee that modern cancer therapies can threaten fertility and that protection of gonadal tissue or other preservation strategies should be treated as part of comprehensive care. Joyce Reineke of the Alliance for Fertility Preservation and Christina Kimball of the Leukemia & Lymphoma Society described equity arguments and estimated that the large majority of cases requiring preservation are associated with chemotherapy, radiation or stem‑cell transplant; they asked that coverage not be limited strictly to a cancer diagnosis because other high‑risk treatments (for example, certain severe autoimmune conditions or sickle cell treatments) can similarly threaten fertility.
Key statutory language discussed: The substitute reads through the Health Care Purchasing Act and the New Mexico Insurance Code and directs that coverage be provided when a patient’s disease or medically necessary treatment may cause infertility. Witnesses and the sponsor emphasized the provision that insurers must not deny coverage on the basis of expected length of life, disability status, perceived quality of life, or other listed criteria — language the sponsor said protects patients from subjective denials.
Committee action: The committee recorded a do‑not‑pass recommendation on the original HB 95 and a do‑pass recommendation on the committee substitute (the transcript records the committee action and roll call on the substitute). Representative N. Chavez explained her no vote on the original as expressing concern about potential premium impacts for state employee plans and asked for more accurate fiscal figures. The sponsor disputed the budget numbers cited during the discussion and said the analysis mischaracterized costs.
Why it matters: Advocates framed the substitute as an equity and access measure that would make fertility‑preservation procedures available to patients undergoing treatments known to cause infertility; insurers and the committee will continue to assess implementation details and fiscal consequences as the bill proceeds.
